Investigational drug · Phase 2
Bivamelagon
Also called: LB54640
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypothalamic Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "Bivamelagon"
First trial start
2024
Jul 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bivamelagon", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypothalamic Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Bivamelagon" as an intervention, largest first.
Rhythm Pharmaceuticals, Inc.Industry
NCT06046443 · 28 participants · Start Jul 11, 2024 · Primary completion Feb 9, 2026
Drug: Bivamelagon; Placebo · For: Hypothalamic Obesity
Sites: Aurora, Colorado; Iowa City, Iowa; Boston, Massachusetts · 10 sites in all
- A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)Enrolling by invitation
Rhythm Pharmaceuticals, Inc.Industry
NCT07156578 · 25 participants (planned) · Start Nov 10, 2025 · Primary completion Apr 15, 2028
Drug: Bivamelagon · For: Hypothalamic Obesity
Sites: Aurora, Colorado; Iowa City, Iowa; Boston, Massachusetts · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.